Skip to main
PRTA
PRTA logo

Prothena (PRTA) Stock Forecast & Price Target

Prothena (PRTA) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 42%
Buy 50%
Hold 4%
Sell 4%
Strong Sell 0%

Bulls say

Prothena Corp PLC has demonstrated a compelling clinical pipeline with investigational therapeutics such as birtamimab, which has shown a significant survival benefit and potential for first-line market positioning in the treatment of AL amyloidosis. The positive outcomes from the Phase 3 VITAL study, particularly in Mayo Stage IV patients, suggest a transformative impact on patient survival rates that could differentiate birtamimab from existing treatments. This unique mechanism of action, which effectively clears amyloid deposits and neutralizes toxic aggregates, positions Prothena for substantial market opportunities, potentially driving growth and enhancing investor confidence.

Bears say

Prothena Corp faces a challenging outlook due to significant risks associated with the clinical viability and market acceptance of its investigational therapeutics, primarily PRX002, birtamimab, and PRX012, which could impact their ability to achieve regulatory approval and peak revenue estimates. Additionally, the company is predicted to incur ongoing net losses until product commercialization, necessitating further capital raises that may dilute shareholder value. The high mortality rate and challenging prognosis of amyloidosis and related conditions exacerbate the company's risk profile, creating further uncertainty regarding the efficacy and market potential of its therapies.

Prothena (PRTA) has been analyzed by 24 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 50% recommend Buy, 4% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prothena (PRTA) Forecast

Analysts have given Prothena (PRTA) a Buy based on their latest research and market trends.

According to 24 analysts, Prothena (PRTA) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prothena (PRTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.